secwatch / observer
8-K filed June 22, 2026, 8:00 AM ET ticker RVMD CIK 0001628171
leadership confidence high sentiment neutral materiality 0.55

Revolution Medicines President R&D Steve Kelsey to retire Jan 2027; becomes senior advisor from July 2026

Revolution Medicines, Inc.

item 5.02item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Steve Kelsey

senior advisor to the chief executive officer
RVMD · Revolution Medicines, Inc.
Effective
2026-07-01
Filed
June 22, 2026, 8:00 AM ET
Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.
Departed

Steve Kelsey

president, research and development
RVMD · Revolution Medicines, Inc.
Effective
2027-01-04
Filed
June 22, 2026, 8:00 AM ET
On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steve Kelsey changed role as senior advisor to the chief executive officer at Revolution Medicines, Inc..

Action
transition
Role
senior advisor to the chief executive officer
Exact text from the filing
Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Steve Kelsey departed as president, research and development at Revolution Medicines, Inc..

Action
retire
Role
president, research and development
Exact text from the filing
On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Revolution Medicines, Inc. shareholders approved Election of two Class III directors to hold office until the 2029 annual meeting at the 2026-06-18 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-18
Exact text from the filing
Nominee Votes For Votes Withheld Broker Non-Votes Alexis Borisy 127,181,172 33,660,532 20,813,641 Mark A. Goldsmith, M.D., Ph.D. 157,681,628 3,160,076 20,813,641
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Revolution Medicines, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-18
Exact text from the filing
Votes For Votes Against Abstentions 181,309,783 206,306 139,256
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Revolution Medicines, Inc. shareholders approved Non-binding advisory approval of named executive officer compensation at the 2026-06-18 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-18
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 155,110,825 5,554,146 176,733 20,813,641
View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-276718
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.